LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives $98.14 Consensus Price Target from Analysts

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the eight analysts that are currently covering the stock, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $98.14.

A number of equities research analysts recently issued reports on LMAT shares. Oppenheimer downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th. Lake Street Capital upped their target price on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target on the stock. Finally, Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Friday, February 28th.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of LeMaitre Vascular stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the transaction, the insider now directly owns 5,564 shares in the company, valued at $456,915.68. The trade was a 26.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO George W. Lemaitre sold 76,868 shares of LeMaitre Vascular stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $85.79, for a total value of $6,594,505.72. Following the completion of the transaction, the chief executive officer now owns 1,796,783 shares of the company's stock, valued at approximately $154,146,013.57. The trade was a 4.10% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 102,009 shares of company stock worth $8,721,836 over the last ninety days. Company insiders own 9.50% of the company's stock.

Institutional Trading of LeMaitre Vascular

Large investors have recently modified their holdings of the company. Opal Wealth Advisors LLC acquired a new stake in shares of LeMaitre Vascular in the 1st quarter worth about $26,000. Smartleaf Asset Management LLC increased its holdings in shares of LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 293 shares during the period. CBIZ Investment Advisory Services LLC increased its holdings in shares of LeMaitre Vascular by 38.5% in the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 117 shares during the period. NBC Securities Inc. acquired a new stake in shares of LeMaitre Vascular in the 1st quarter worth about $36,000. Finally, Geneos Wealth Management Inc. increased its holdings in shares of LeMaitre Vascular by 250.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after acquiring an additional 398 shares during the period. Institutional investors and hedge funds own 84.64% of the company's stock.

LeMaitre Vascular Price Performance

Shares of NASDAQ LMAT traded up $1.28 on Thursday, hitting $82.68. The company's stock had a trading volume of 227,711 shares, compared to its average volume of 167,290. LeMaitre Vascular has a 12-month low of $71.42 and a 12-month high of $109.58. The company has a market capitalization of $1.87 billion, a price-to-earnings ratio of 45.18, a price-to-earnings-growth ratio of 2.22 and a beta of 0.86. The stock has a 50 day moving average of $84.07 and a 200-day moving average of $92.18.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). The firm had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business's quarterly revenue was up 12.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.44 EPS. Sell-side analysts expect that LeMaitre Vascular will post 1.94 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, May 29th. Shareholders of record on Thursday, May 15th will be paid a $0.20 dividend. The ex-dividend date of this dividend is Thursday, May 15th. This represents a $0.80 dividend on an annualized basis and a yield of 0.97%. LeMaitre Vascular's payout ratio is currently 40.40%.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.